Anti-infection
-
BA1871 PF-4878691Summary: PF-4878691 (3M-852A) is an orally active agonist. - BA1873 MiravirsenSummary: Miravirsen (SPC-3649) is a potent inhibitor of miR-122 biogenesis.
- BA1874 FilibuvirSummary: Filibuvir is an orally effective, selective non-nucleoside inhibitor of the non-structural 5B protein RNA-dependent RNA polymerase (RdRp).
- BA1876 IDX184Summary: IDX184 is a potent, orally active replication inhibitor.
- BA1877 Nucleoside-Analog-2Summary: Nucleoside-Analog-2 is a 4'-azacytidine analog that targets hepatitis C virus replication.
- BA1880 SamatasvirSummary: Samatasvir (IDX71) is a potent, orally active replication inhibitor.
- BA1883 SetrobuvirSummary: Setrobuvir (ANA598) is an orally active non-nucleoside polymerase inhibitor.
- BA1886 Nucleoside-Analog-1Summary: Nucleoside-Analog-1, an analog of antiviral nucleoside R1479, was used in the synthesis of HCV antiviral nucleoside analogs.
- BA1887 KIN1400Summary: KIN1400 is a potent activator.
-
BA1891 VoxilaprevirSummary: Voxilaprevir (GS-9857) is a non-covalent, reversible protease inhibitor (PI) with pan-antiviral activity.